Saturday, October 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1eli lillyobesityincretin

BusinessWorld reports new Eli Lilly obesity trial weight-loss results

The report points to weight reductions from the company's obesity drug trials without detailing the candidate, dose or endpoints.

MH
By Maren Holt · Senior Reporter, GLP-1
Oct 20 10:35 ETSource: BusinessWorld Online

The wire

  1. 01BusinessWorld reports that Eli Lilly drug trials showed weight-loss results the outlet describes as record breaking.
  2. 02Eli Lilly's incretin pipeline is closely watched by prescribers and compounders tracking supply and competition in obesity care.
  3. 03No trial name, candidate, dose, sample size or endpoint accompanies the report, so the underlying data cannot be assessed.

From the source

eli lilly drug trials show record breaking weight loss results

Read at bworldonline.com
PeptiPrescribed peptides from $99/moSee all →